Category: 31699-14-6

On April 30, 2007, Karade, Hitendra; Sathe, Manisha; Kaushik, M. P. published an article.Name: 2-Amino-4-(4-iodophenyl)thiazole The title of the article was An efficient method for the synthesis of 2-aminothiazoles using silica chloride as a heterogeneous catalyst. And the article contained the following:

Preparation of 2-aminothiazoles under mild reaction conditions with quant. yields using silica chloride as an effective heterogeneous catalyst is reported. The experimental process involved the reaction of 2-Amino-4-(4-iodophenyl)thiazole(cas: 31699-14-6).Name: 2-Amino-4-(4-iodophenyl)thiazole

The Article related to aminothiazole preparation ketone thiourea silica chloride catalyst, thiazole amino preparation ketone thiourea silica chloride catalyst, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Name: 2-Amino-4-(4-iodophenyl)thiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On January 20, 2018, Liessi, Nara; Cichero, Elena; Pesce, Emanuela; Arkel, Maria; Salis, Annalisa; Tomati, Valeria; Paccagnella, Matteo; Damonte, Gianluca; Tasso, Bruno; Galietta, Luis J. V.; Pedemonte, Nicoletta; Fossa, Paola; Millo, Enrico published an article.Application In Synthesis of 2-Amino-4-(4-iodophenyl)thiazole The title of the article was Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools. And the article contained the following:

The most common CF mutation, F508del, impairs the processing and gating of CFTR protein. This deletion results in the improper folding of the protein and its degradation before it reaches the plasma membrane of epithelial cells. Present correctors, like VX809 only induce a partial rescue of the mutant protein. Our previous studies reported a class of compounds, called aminoarylthiazoles (AATs), featuring an interesting activity as correctors. Some of them show additive effect with VX-809 (I) indicating a different mechanism of action. In an attempt to construct more interesting mols., it was thought to generate chem. hybrid compounds, blending a portion of VX-809 merged to the thiazole scaffold. This approach was guided by the development of QSAR analyses, which were performed based on the F508del correctors so far disclosed in the literature. This strategy was aimed at exploring the key requirements turning in the corrector ability of the collected derivatives and allowed us to derive a predictive model guiding for the synthesis of novel hybrids as promising correctors. The new mols. were tested in functional and biochem. assays on bronchial CFBE41o-cells expressing F508del-CFTR showing a promising corrector activity. The experimental process involved the reaction of 2-Amino-4-(4-iodophenyl)thiazole(cas: 31699-14-6).Application In Synthesis of 2-Amino-4-(4-iodophenyl)thiazole

The Article related to thiazole vx809 hybrid cystic fibrosis deletion mutation corrector qsar, aminoarylthiazole, cftr, corrector, cystic fibrosis, qsar, vx809, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Application In Synthesis of 2-Amino-4-(4-iodophenyl)thiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On December 31, 2009, Muthuppalniappan, Meyyappan; Thomas, Abraham; Kumar, Sukeerthi; Margal, Sanjay; Khairatkar-Joshi, Neelima; Mukhopadhyay, Indranil; Gullapalli, Srinivas published a patent.Reference of 2-Amino-4-(4-iodophenyl)thiazole The title of the patent was Preparation of quinazolinedione derivatives as TRPA1 modulators. And the patent contained the following:

The title compounds I [ring A = (hetero)aryl, heterocyclyl, cycloalkyl; R1, R2 = H, OH, alkyl, etc.; R3, R4 = H, OH, halo, etc.; or R3 and R4 may be joined together to form (un)substituted 3-7 membered (un)saturated cyclic ring which may optionally include one or more heteroatom or group selected from O, S, C(O), S(O)0-2, (un)substituted NH; R5 = H, OH, alkyl, etc.; R6 = H, CN, NO2, etc.; n = 0-5], useful as TRPA (Transient Receptor Potential subfamily A) modulators for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1), were prepared E.g., a multi-step synthesis of II, starting from 2-amino-6-nitrobenzoic acid and urea, was given. Exemplified compounds I were screened for TRPA1 activity. For example, II showed 90.73% inhibition at 10.0 μM using the 45Calcium Uptake Assay. Also provided are processes for preparing compounds I, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. The experimental process involved the reaction of 2-Amino-4-(4-iodophenyl)thiazole(cas: 31699-14-6).Reference of 2-Amino-4-(4-iodophenyl)thiazole

The Article related to quinazolinedione preparation transient receptor potential channel trpa1 modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Reference of 2-Amino-4-(4-iodophenyl)thiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On January 29, 2004, Vaccaro, Wayne; Yang, Bingwei Vera; Kim, Soong-hoon; Huynh, Tram; Tortolani, David R.; Leavitt, Kenneth J.; Li, Wenying; Doweyko, Arthur M.; Chen, Xiao-tao; Doweyko, Lidia published a patent.Recommanded Product: 31699-14-6 The title of the patent was Preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of the glucocorticoid receptor. And the patent contained the following:

Title compounds I [R-R4 = H, alk(en/yn)yl, alkoxy, aryl, etc.; Z = carboxamido, alkylamino, etc.] are prepared For instance, 2-amino-4,5-dimethylthiazole is coupled to the acid derived from the cycloaddition of methacrylic acid and anthracene (CH3CN, EDCI, Et3N, HOAt, 18 h) to give II. I are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders. The experimental process involved the reaction of 2-Amino-4-(4-iodophenyl)thiazole(cas: 31699-14-6).Recommanded Product: 31699-14-6

The Article related to modulator glucocorticoid receptor bicyclo amide preparation, Alicyclic Compounds: Bicyclic Compounds, Including Azulenes, Heptalenes, and Pentalenes and other aspects.Recommanded Product: 31699-14-6

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On October 1, 2009, Muthuppalniappan, Meyyappan; Kumar, Sukeerthi; Thomas, Abraham; Khairatkar-Joshi, Neelima; Mukhopadhyay, Indranil published a patent.Synthetic Route of 31699-14-6 The title of the patent was Preparation of phthalimide derivatives as TRPA1 modulators. And the patent contained the following:

The present invention provides TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds I [ring A = (hetero)aryl, heterocyclyl, cycloalkyl; R1 = H, OH, (un)substituted alkyl, etc.; R2 = H, CN, NO2, etc.; R3, R4 = H, OH, halo, etc.; or R3 and R4 may be joined together to form (un)substituted 3-7 membered (un)saturated cyclic ring which may optionally include at least one heteroatom such as O, S, (un)substituted NH, C(O), S(O)0-2; R5 = H, OH, (un)substituted alkyl, etc.] are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1) modulators. Forty-four compounds I were prepared Thus, coupling the acid II (multi-step synthesis was given) with 4-isopropylaniline afforded the title compound III. Exemplified compounds I were screened for TRPA1 antagonist activity using the 45Calcium uptake assay (data given). Also provided are processes for preparing compounds I, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. The experimental process involved the reaction of 2-Amino-4-(4-iodophenyl)thiazole(cas: 31699-14-6).Synthetic Route of 31699-14-6

The Article related to phthalimide amide preparation transient receptor potential a trpa1 modulator, isoindolylacetamide preparation transient receptor potential a trpa1 modulator, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Synthetic Route of 31699-14-6

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On May 15, 2008, Yang, Bingwei Vera; Doweyko, Lidia M.; Vaccaro, Wayne; Huynh, Tram N.; Tortolani, David R.; Dhar, T.g. Murali published a patent.Name: 2-Amino-4-(4-iodophenyl)thiazole The title of the patent was N-Heteroaryl carboxamides as modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula I an enantiomer, diastereomer, tautomer, solvate (e.g. a hydrate), or a pharmaceutically-acceptable salt, thereof. Also provided are pharmaceutical compositions and methods of treating metabolic and inflammatory- or immune-associated diseases or disorders using said compounds Compounds of formula I wherein M is (un)substituted alkyl, cycloalkyl, (hetero)aryl and heterocyclyl; Ma and Za are independently a bond and C1-3 alkylene; Q is H, (un)substituted C1-4 alkyl; Q and R6 taken together to form a 3- to 6-membered cycloalkyl; Q and M taken together to form a 3- to 7-membered heterocyclic ring; Z is cycloalkyl, heterocyclyl and (hetero)aryl; R1 – R4 are independently H, halo, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, NO2, CN, OH and derivatives, etc.; R6 is (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, CHO, acyl, CO2H and derivatives, etc.; R7 is halo, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, NO2, CN, OH and derivatives, etc.; R22 is H, (un)substituted alkyl, CO-alkyl, CO2-alkyl, SO2-alkyl, alkoxy, (un)substituted amino, (hetero)aryl, heterocyclyl, and cycloalkyl; and their enantiomers, diastereoisomers, and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 2,2-diphenyl-1-methylcyclopropane-1-carboxylic acid with 2-aminothiazole. All the invention compounds were evaluated for their GR and AP-1 modulatory activity. From the assay, it was determined that compound II exhibited Ki value of 103.8 % RBA. The experimental process involved the reaction of 2-Amino-4-(4-iodophenyl)thiazole(cas: 31699-14-6).Name: 2-Amino-4-(4-iodophenyl)thiazole

The Article related to heteroaryl carboxamide preparation glucocorticoid receptor ap1 nfkb modulator, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Name: 2-Amino-4-(4-iodophenyl)thiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On August 31, 2013, Koppireddi, Satish; Komsani, Jayaram Reddy; Avula, Sreenivas; Pombala, Sujitha; Vasamsetti, Satishbabu; Kotamraju, Srigiridhar; Yadla, Rambabu published an article.SDS of cas: 31699-14-6 The title of the article was Novel 2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamides as antioxidant and/or anti-inflammatory compounds. And the article contained the following:

A series of novel N-(4-aryl-1,3-thiazol-2-yl)-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamides(4a-k) I and N-(1,3-benzothiazol-2-yl)-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamide derivatives (4l-o) II are synthesized and evaluated for their anti-inflammatory and antioxidant activity (DPPH radical scavenging, superoxide anion scavenging, lipid peroxide inhibition, erythrocyte hemolytic inhibition). Compounds 4k and 4l have exhibited good antioxidant activity in four assays, while compounds 4c, 4d, 4m, 4n and 4o have shown good DPPH radical scavenging efficacy. Compounds 4a, 4h, 4i, 4k, 4m and 4n have possessed excellent anti-inflammatory activity. N-[4-(o-methoxyphenyl)-1,3-thiazol-2-yl]-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamide (4k) and N-(6-nitro-/methoxy-1,3-benzothiazol-2-yl)-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamide (4m and 4n) have exhibited both antioxidant and anti-inflammatory activities. The experimental process involved the reaction of 2-Amino-4-(4-iodophenyl)thiazole(cas: 31699-14-6).SDS of cas: 31699-14-6

The Article related to dioxothiazolidinylacetamide antioxidant antiinflammatory, anti-inflammatory activity, erythrocyte hemolysis, lipid peroxidation, n-(1,3-benzothiazol-2-yl)-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamide, n-(4-aryl-1,3-thiazol-2-yl)-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamide, superoxide anion and dpph radical scavenging and other aspects.SDS of cas: 31699-14-6

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica